4 FDA drug decisions on the horizon

03/18/2013 | Investor's Business Daily

The FDA is poised to decide on Biogen Idec's multiple sclerosis drug BG-12 by March 28, while United Therapeutics is set to receive a verdict by March 31 for the lung drug Remodulin. Johnson & Johnson's diabetes drug Invokana and Map Pharmaceuticals' migraine drug Levadex are also set to receive federal decisions by March 31 and April 15, respectively.

View Full Article in:

Investor's Business Daily

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA